Plum SEC
Menu
Korean Market
Privacy Policy
Korean Market
Star Rating
Reset (View All)
★★★★★
★★★★
★★★
★★
★
★
★
★★
★★★
★★★★
★★★★★
All Disclosures
Search
EXCH
Kolon TissueGene
★
Kolon TissueGene Announces Topline Data from TG-C Phase 3 Knee Osteoarthritis Trial, Co-Primary Endpoints Not Met
07/20/2026 04:56 PM
EXCH
Kolon TissueGene
★
Kolon TissueGene Correction Disclosure: Minimal Reduction in Damage Claim, Negligible Impact on Shareholder Value
07/09/2026 05:04 PM
EXCH
Kolon TissueGene
★
Kolon TissueGene Wins Damages Lawsuit: Seoul High Court Mediation Finalized with Zero Payment Obligation
07/03/2026 04:15 PM
EXCH
Kolon TissueGene
★
Kolon TissueGene Amends Lawsuit Disclosure: Claim Amount Slightly Reduced and Some Plaintiffs Withdraw
07/01/2026 04:47 PM
EXCH
Kolon TissueGene
★
Kolon TissueGene Amends Lawsuit Disclosure with Partial Withdrawal of Plaintiffs and Reduced Claim
06/23/2026 04:37 PM
EXCH
Kolon TissueGene
★★
Derivative Valuation Loss of 94.9 Billion Won, 42.73% of Equity
05/15/2026 05:20 PM
OWNR
Kolon TissueGene
★
Kolon Increases Share Count via Exchangeable Bond Conversion
05/15/2026 05:06 PM
PERI
Kolon TissueGene
★
Kolon TissueGene Q1 2026: Phase 3 Trial on Track, Net Loss Swells Due to Large Derivative Valuation Loss
05/15/2026 04:30 PM